Squarepoint’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Squarepoint’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,166	Closed	-$46K	–	3701
2022 Q3	$46K	Sell	2,166 -1,069	-33%	-$28.8K	﹤0.01%	2858
2022 Q2	$78K	Buy	3,235 +1,668	+106%	+$56.8K	﹤0.01%	2663
2022 Q1	$78K	Sell	1,567 -619	-28%	-$30.6K	﹤0.01%	2634
2021 Q4	$153K	Buy	2,186 +1,238	+131%	+$104K	﹤0.01%	2810
2021 Q3	$88K	Sell	948 -5,275	-85%	-$501K	﹤0.01%	2696
2021 Q2	$625K	Buy	6,223 +4,872	+361%	+$475K	﹤0.01%	1976
2021 Q1	$126K	Sell	1,351 -412	-23%	-$41.8K	﹤0.01%	2849
2020 Q4	$145K	Sell	1,763 -10,684	-86%	-$911K	﹤0.01%	2625
2020 Q3	$1.07M	Buy	12,447 +8,909	+252%	+$1.04M	0.01%	961
2020 Q2	$329K	Buy	+3,538	New	+$195K	0.01%	1543
2019 Q4	–	Sell	-15,104	Closed	-$214K	–	2891
2019 Q3	$214K	Buy	+15,104	New	+$316K	﹤0.01%	2050
2019 Q1	–	Sell	-490	Closed	-$24K	–	2504
2018 Q4	$24K	Sell	490 -1,708	-78%	-$93.7K	﹤0.01%	1862
2018 Q3	$160K	Buy	2,198 +1,682	+326%	+$111K	﹤0.01%	1823
2018 Q2	$43K	Buy	+516	New	+$49.8K	﹤0.01%	1698

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Squarepoint's VBIV Position: Q4 2022 in Review

Squarepoint sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2022, closing a stake of 2,166 shares — an estimated $46K sold.

Squarepoint first reported a position in VBIV in Q2 2018 and held it in 14 quarters. The position peaked at $1.07M in Q3 2020. 111 funds tracked by Wall St. Rank hold VBIV as of Q4 2022.

Squarepoint reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2022 after selling out during the quarter.
Squarepoint sold 2,166 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2022, an estimated $46K.
Squarepoint first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2018 and held it in 14 quarters.
Squarepoint's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $1.07M in Q3 2020.
111 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2022.

Based on Squarepoint's 13F filing for Q4 2022, filed 14 Feb 2023.